BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month
During May, Mental Health Awareness Month,
“Sixty million people in
The campaign continues to show BrainsWay’s commitment to raising awareness about mental health, as well as modern treatment options, including Deep TMS™. BrainsWay’s Deep TMS treatment is FDA cleared for patients with depression, including depression with comorbid anxiety symptoms (anxious depression), obsessive-compulsive disorder (OCD), and tobacco addiction. Through a padded helmet, electromagnetic pulses are delivered to target deep brain structures to treat the patient’s symptoms. The treatment is non-invasive, drug-free, and patients can resume normal activities, such as driving, immediately after the session.
To participate in the campaign, share photos of life moments you wouldn’t want to miss and include the hashtag, #DontMissAnotherMoment. You can also share and comment on BrainsWay social media posts on Facebook, Twitter and/or Instagram.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be prefaced by the words “intends”, “may”, “will”, “expects”, “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements and their implications are based on the current expectations of the Company’s management only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. . In addition, the pilot data presented here, including outcomes/results, patient safety information, and adverse event data, remain subject to further analysis and may be subject to additional changes. Some results as expressed here may be subject to further analysis, modification and/or statistical penalties. In addition, historical results or the conclusions of scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted in the same way light of further research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: insufficient financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in initiating and/or completing planned clinical studies and trials; failure to obtain regulatory approvals within the Company’s timelines, or at all; failure to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or failure to develop necessary improvements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in applicable laws and rules and regulations; adverse market perception and acceptance of Deep TMS technology; insufficiency or delays in reimbursement by third-party payers, including insurance companies and Medicare; inability to market Deep TMS, including internationally, by the Company or through third-party distributors; development of products by competitors; failure to develop and introduce new technologies, products and applications on a timely basis; the continuation and/or worsening of the global supply chain crisis and its impact on the Company’s ability to source components, meet customer demand, fulfill orders, maintain price levels and meeting the Company’s service needs; and the effect of the COVID-19 global health pandemic on our business and the continued uncertainty and market impact related thereto.
Any forward-looking statements in this press release speak only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable securities laws. More detailed information on the risks and uncertainties affecting the Company can be found under the heading “Risk Factors” in the documents filed by the Company with the
2022 GlobeNewswire, Inc., source